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Abstract: Inflammation and antioxidant capacity have been associated with colorectal and breast
cancer. We computed the dietary inflammatory index (DII®), and the total dietary non-enzymatic
antioxidant capacity (NEAC) and associated them with colorectal and breast cancer risk in the
population-based multi case-control study in Spain (MCC-Spain). We included 1852 colorectal cancer
and 1567 breast cancer cases, and 3447 and 1486 population controls, respectively. DII score and
NEAC were derived using data from a semi-quantitative validated food frequency questionnaire.
Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence
intervals (95%CI) for energy-adjusted DII (E-DII), and a score combining E-DII and NEAC. E-DII was
associated with colorectal cancer risk (OR = 1.93, highest quartile versus lowest, 95%CI:1.60–2.32;
p-trend: <0.001); this increase was observed for both colon and rectal cancer. Less pronounced
increased risks were observed for breast cancer (OR = 1.22, highest quartile versus lowest,
95%CI:0.99–1.52, p-trend: >0.10). The combined score of high E-DII scores and low antioxidant values
were associated with colorectal cancer risk (OR = 1.48, highest quartile versus lowest, 95%CI: 1.26–1.74;
p-trend: <0.001), but not breast cancer. This study provides evidence that a pro-inflammatory diet is
associated with increased colorectal cancer risk while findings for breast cancer were less consistent.
Keywords: colorectal cancer; breast cancer; diet; dietary inflammatory index; antioxidants; NEAC;
case-control study; MCC-Spain
1. Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide [1]. Beyond non-modifiable
risk factors such as age, male sex, family history of CRC, and genetic predisposition [2], epidemiological
studies have identified a number of modifiable factors that have a direct impact on CRC risk, for example
cigarette smoking, which increases risk [3], and regular use of aspirin, which decreases risk [4]. Regarding
nutritional factors, consuming processed and red meat, alcoholic beverages, and being overweight or
obese increases the risk of developing CRC; whereas being physically active, consuming whole grains,
foods rich in fiber including fruits and vegetables, dairy products, and calcium supplements decrease
CRC risk [5].
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Among females, breast cancer (BC) and CRC are the two most frequently diagnosed cancers [6,7].
Age, BRCA1 or BRCA2 genes mutations, family history of BC or ovarian cancer, radiation, hormonal
factors, physical inactivity, alcohol consumption, tobacco smoking and physical inactivity are important
risk factors for BC [8,9]. The role of diet, however, remains controversial [9].
Despite that CRC and BC are different cancers affecting different organs, they share similar risk
factors. Scientific evidence has shown that chronic inflammation and oxidative stress predispose the
pathogenesis of numerous diseases, including CRC and BC [10–13]. Additionally, it has been observed
that oxidative stress produces DNA damage and increases cancer risk, partially mediated through
inflammation, suggesting that both mechanisms are also related [14,15].
Diet may play a role in the regulation of chronic inflammation, as shown by the relation between
dietary factors and blood levels of inflammatory markers [16–18]. There have been several approaches
to assess the inflammatory potential of the overall diet, beyond the study of single nutrients and foods,
and the most widely used is the dietary inflammatory index (DII®), which was specifically designed to
assess and offer quantitative information about the inflammatory potential of the diet [19]. The DII
has been shown to be associated with various biomarkers of inflammation in several studies [20–22]
including those in Europe [23–25]. The relation between diet and oxidative stress also has been
evaluated, but the molecular mechanisms are still under study [26]. The non-enzymatic antioxidant
capacity (NEAC) has been proven to be a useful tool to estimate the total dietary antioxidant content,
as it takes into account all the antioxidants and bioactive compounds present in the diet and the
synergistic effects between them [27,28].
Numerous epidemiological studies have assessed the association between DII and energy-adjusted
(E-DII) scores and CRC and BC risk, supporting the hypothesis that a pro-inflammatory diet is related
to CRC risk [29]. The evidence for BC is less clear [30–32]. The role of NEAC has also been evaluated
in several cancer sites, including CRC and BC. Despite that some studies indicated no clear association
between NEAC and CRC risk [33,34], others have observed statistically significant decreased risk for
CRC [28,35], as well as for BC risk [36,37].
Thus far, studies essentially have focused on assessing the role of the inflammatory potential
of the diet on cancer risk, without considering the plausible combined effect of a global indicator of
NEAC. Using the newly constructed E-DII in the population-based multi-case-control (MCC)-Spain
study our aim is to analyze the association between the inflammatory potential of the diet, and the risk
of developing BC and CRC, as well as among tumor subtypes. A second aim of the present study is to
elucidate the relation between E-DII and NEAC, and to evaluate whether having an anti-inflammatory
and antioxidant diet affects the risk of developing CRC and BC.
2. Materials and Methods
2.1. Study Population and Design
MCC-Spain is a population-based multicenter case-control study designed to investigate the etiology
of the principal cancer sites (colorectal, breast, prostate, and gastric tumors, and chronic lymphocytic
leukemia) in adults. The study design and protocol have been described in detail elsewhere [38].
The MCC-Spain enrolled cases and controls from 12 Spanish provinces (Asturias, Barcelona, Cantabria,
Girona, Granada, Guipúzcoa, Huelva, León, Madrid, Murcia, Navarra, and Valencia) from 2008 to
2013. All participants who were eligible to take part in the study and agreed to participate signed
an informed consent. The study protocol of the MCC-Spain was approved by all the Ethics Committees
of the participating institutions and followed national and international directives on ethics and data
protection [38].
The CRC sub-study included 1852 cases and 3347 controls, and the BC sub-study included 1486
cases and 1652 controls (Figure 1). Newly diagnosed cancer cases were ascertained through the oncologic
or digestive units of the participating hospitals. All CRC and BC cases were histologically confirmed.
CRC cases were classified according to the International Classification of Diseases 10th Revision as C18,
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C19, C20, D01.0, D01.1, and D01.2 (including cancer of the colon or rectum) whereas BC cases were
classified as C50, D05.1, and D05.7. Controls were randomly selected from lists of primary care centers
located in the catchment area of hospitals from where the cases came. They were frequency matched to
cases on age, sex, and region. As reported elsewhere, the mean response rate of controls was 53%, and
differed by region [38].
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2.2. Epidemiological Data Collection
Face-to-face interviews were carried out at baseline by trained personnel using a structured
computerized epidemiological questionnaire to assess data on socio-demographic, lifestyle, environmental
exposure, residential history, personal/family medical history, drug use, and weight information at
different ages. The questionnaire is available at http://www.mccspain.org.
Information on dietary data was assessed using a self-administered semi-quantitative food
frequency questionnaire (FFQ), which was an adapted version of a Spanish-validated FFQ [39] as it
was modified to include regional products. Details on the validation study of this FFQ are provided
elsewhere. In brief, the de-attenuated correlation coefficients between the second questionnaire and
diet records ranged from 0.45 for vitamin A to 0.91 for alcohol [40]. The MCC-study FFQ included
portion sizes and photos to assess dietary information with the timeframe referring to the preceding
year. Further, cross-check questions on food groups intakes were designed to adjust the frequency of
food consumption and to reduce misreporting of food groups with large numbers of items. A total of
140 items were obtained. Information on total energy intake and intake of both macronutrients and
micronutrients, as well as alcohol consumption were derived from Spanish food composition tables
and other specific sources [41].
2.3. Dietary Non-Enzymatic Antioxidant Capacity and Dietary Inflammatory Index Assessment
The assessment of the dietary NEAC in the MCC-Study has been previously described in detail [28].
Briefly, for the present study, dietary NEAC was estimated using the Trolox equivalent antioxidant
capacity (TEAC-ABTS, referred from now on as TEAC; mmol TE/Kg) using published values of NEAC
content in food, and was assessed with and without coffee information. The MCC-study FFQ food
items were matched with the corresponding dietary NEAC values, and the average daily NEAC
consumption (using TEAC) was estimated for each participant.
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DII scores were calculated using a method previously reported by Shivappa et al. [19]. Briefly,
the scoring algorithm based on extensive review of the literature focused on the effect of diet on six
inflammatory biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP) from 1950 to 2010. A total of 45
food parameters, including macronutrients and micronutrients, were scored according to whether they
increased (+1), decreased (-1), or had no effect (0) on these inflammatory biomarkers. These scores
were weighted based on study design. To avoid the arbitrariness resulting from simply using raw
consumption amounts, intakes of foods and nutrition were standardized to a representative range of
dietary intake based on actual human consumption in 11 populations living in different countries across
the world that provided an estimate of a mean and standard deviation for each parameter. These values
were converted to a proportion (with values from 0 to 1). Each proportion was doubled, and then 1 was
subtracted to achieve a symmetrical distribution around a mean of ≈0. Each of these values was then
multiplied by an overall food parameter-specific inflammation score. All the food parameter-specific
DII scores were summed to create the overall DII scores for each subject. Energy-adjusted DII (E-DII)
scores were calculated by converting raw dietary components to amount per 1000 kcal. To compute
the E-DII scores, we relied on an energy-adjusted global database. Higher E-DII scores indicate more
pro-inflammatory diets, while lower E-DII scores represent anti-inflammatory diets. In this study,
data were available for a total of 30 food parameters (carbohydrate, protein, total fat, alcohol, fiber,
cholesterol, saturated fatty acid, monounsaturated fatty acid, polyunsaturated fatty acid, vitamin A,
vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, folic acid,
iron, magnesium, zinc, anthocyanidins, flavan3ols, flavones, flavonols, flavonones, isoflavones, garlic,
and onion) to calculate the E-DII scores. E-DII scores were used in all analyses in this study.
2.4. Statistical Analyses
Baseline dietary and sociodemographic characteristics were examined using means and standard
deviations (SD) for continuous variables and percentages for categorical variables by CRC and BC
cases and controls, and across E-DII quartiles. Differences between cases and controls were assessed
using Student’s t-test for continuous variables normally distributed, Wilcoxon rank-sum test for
continuous variables non-normally distributed, and Pearson χ2 test for categorical variables. The E-DII
was analyzed as a continuous variable (one-unit increment) and as a categorical variable, expressed as
quartiles based on the sex-specific distribution in the control group (CRC or BC controls). The first
E-DII quartile was treated as reference category (meaning lowest inflammatory potential of the diet).
The odds ratios (OR) and the corresponding 95% confidence intervals (95%CI) for the association
between E-DII and CRC and BC risk were estimated using unconditional logistic regression models.
Analyses also were conducted separately by CRC anatomic subsites (colon and rectum) and BC
subtypes (HR+, HER2+, TN). Tests for dose-response trend were estimated by including the exposure
variable as continuous ordinal (scored from 1 to 4) in the regression model.
For analyses where CRC was the main outcome, two different models are presented: (1) A simple
model adjusting for age, sex, study area, and educational level (less than primary, primary, high school,
university); (2) a final model, additionally adjusting for family history as first-degree relative of CRC
(no, yes, unknown), smoking status (never, current, former), BMI (kg/m2) one year before recruitment,
leisure-time physical activity calculated for the last 10 years of life, excluding the last 2 years previous
to the interview (inactive, moderately active, active, very active), and non-steroidal anti-inflammatory
drugs use (NSAIDs; yes, no, unknown).
Effect-measure modification by NSAIDs (yes, no), physical activity (inactive, active), BMI
(<25, ≥25 kg/m2), and smoking status (never, ever) was evaluated by including interaction terms and by
stratified analysis. The models with and without the interaction terms were compared using the likelihood
ratio test (LRT).
Likewise, two different models were evaluated to study the relation between E-DII and BC
risk: (1) A simple model (previously defined, excepting sex); (2) a final model further adjusted by
family history first degree of BC (no, yes, unknown), smoking status, BMI, physical activity, hormonal
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replacement therapy use (HRT; no, yes, unknown), oral contraceptive use (OC; no, yes, unknown),
age at menarche (<13, ≥13 years, unknown), age at first pregnancy (no children, <20, 20–24, 25–29,
>29 years), number of children, and menopausal status (premenopausal, postmenopausal).
Potential effect-measure modification of the association between E-DII and BC risk also was
assessed using a LRT in the mutually adjusted model by physical activity, BMI, smoking status,
menopausal status (premenopausal, postmenopausal), HRT use (yes, no), and OC use (yes, no).
Three sensitivity analyses for both CRC and BC final models were performed: (1) Excluding
those participants who had more than 6 months between the data of diagnosis and the interview
(final models included 1596 CRC cases and 1140 BC cases); (2) further adjusting the final CRC and
BC models by energy intake from non-alcohol sources and alcohol consumption; (3) restricting the
analyses to non-drinkers.
To assess the second aim of the present study, two approaches were conducted. First, an inflammatory
and antioxidant profile was designed, and it was used as the main exposure variable in both CRC and BC
final models. A value of 0, 1, 2, and 3 was assigned to the first, second, third, and fourth quartile of E-DII
(lower scores indicate lower inflammatory potential of diet), whereas a value of 3, 2, 1, and 0 was assigned
to the first, second, third, and fourth quartile of NEAC (using TEAC; higher score indicates higher
antioxidant capacity of diet). When CRC was evaluated, quartiles values were sex-specific. For each
participant, the values received were summed to assess the profile score. The profile ranged from 0
(less inflammatory and high antioxidant) to 6 (high inflammatory and less antioxidant). Linear trend
tests were used to calculate the OR for the profile as a continuous variable (1 point-increment). Second,
a combined categorical variable including both indicators (E-DII and TEAC) was created using median
values (sex-specific for CRC). This four-category variable was used as the main exposure variable in final
models. Those participants classified having high antioxidant and low inflammatory potential of diet
were selected as the reference category. Potential effect-measure modification of the association between
E-DII+NEAC score and both cancer outcomes was evaluated by vegetable intake (low, high), all meat
intake (low, high), and fiber intake (low, high).
Statistical analyses were conducted using R: A language and environment for statistical computing,
version 3.5 (R Core Team, 2018). All statistical tests were two-sided and statistical significance was set
at p < 0.05.
3. Results
3.1. Characteristics of Cases and Controls in the MCC-Study
The present study included 1852 CRC and 1486 BC cases, and 3447 and 1652 population controls,
respectively. The main characteristics of cases and controls are presented in Table 1. Briefly, CRC cases
compared to controls had higher E-DII scores, indicating a more pro-inflammatory diet, tended to be
older, heavier, and less active, and more frequently classified as having a low education and a family
history of CRC (p < 0.001). BC cases compared to controls also had higher E-DII scores, tended to
be younger, and reported more frequently being smokers, premenopausal, and having a first-degree
history of BC (p < 0.001). Similar distributions were observed among BC cases and controls regarding
HRT, OC use, and age at first pregnancy (p > 0.05).
Characteristics of participants in the control group across quartiles of E-DII are shown in Table 2.
Participants in the highest quartile (Q4) were younger, consumed more calories (without considering
alcohol) and alcohol, reported being current smokers, and less active compared with those in the
lowest quartile (Q1) (p < 0.001). Among female controls, those classified in the Q4 compared with Q1
tended to be premenopausal and were OC but not HRT users. No differences were observed across
quartiles regarding age at menarche, age at first pregnancy, and number of children (all p > 0.30).
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Table 1. Characteristics of colorectal cancer and breast cancer cases and controls in the Multi
Case-Control Study in Spain (MCC-Spain). Numbers may differ due to missing values.
Colorectal Cancer Study (n = 5299) Breast Cancer Study (n = 3138)
Controls CRC Cases
p-Value 1
Controls BC Cases
p-Value 1
mean(sd)/N(%) mean(sd)/N(%) mean(sd)/N(%) mean(sd)/N(%)
Sex
Male 1781 (51.7%) 1183 (63.9%)
<0.001
- -
Female 1666 (48.3%) 669 (36.1%) 1652 (52.6) 1486 (47.4)
E-DII score −0.39 (1.9) 0.03 (1.9) <0.001 −0.75 (1.8) −0.50 (1.9) <0.001
Total dietary NEAC
(without coffee)
TEAC (µmol TE/day) 4.01 (1.83) 3.96 (1.82) 0.33 3.74 (1.68) 3.75 (1.72) 0.98
Age (years) 63.2 (11.7) 66.8 (10.6) <0.0012 59.0 (13.0) 56.2 (12.4) <0.001
BMI (kg/m2) 26.6 (4.4) 27.6 (4.5) <0.001 25.7 (4.8) 25.9 (4.6) 0.40
Energy intake (without
alcohol; kcal/day) 1805 (535) 1900 (588) <0.001 1727 (499) 1808 (529) <0.001
Ethanol intake (g/day) 11.0 (15.9) 12.0 (19.3) <0.0012 4.97 (8.2) 5.16 (9.3) 0.29 2
Physical activity
Inactive 1316 (38.6%) 949 (51.2%)
<0.001
628 (38.3%) 613 (41.3%)
0.40
Moderately active 501 (14.7%) 214 (11.6%) 305 (18.6%) 256 (17.2%)
Active 416 (12.2%) 159 (8.59%) 214 (13.1%) 190 (12.8%)
Very active 1178 (34.5%) 530 (28.6%) 491 (30.0%) 427 (28.7%)
Education level
Less than primary 604 (17.5%) 578 (31.2%)
<0.001
272 (16.5%) 209 (14.1%)
0.07
Primary 1120 (32.5%) 715 (38.6%) 500 (30.3%) 491 (33.0%)
High school 992 (28.8%) 373 (20.1%) 520 (31.5%) 492 (33.1%)
University 731 (21.2%) 186 (10.0%) 360 (21.8%) 294 (19.8%)
Tobacco smoking
Never smoker 1522 (44.3%) 766 (41.6%)
<0.001
991 (60.1%) 822 (55.5%)
0.004Former smoker 1204 (35.1%) 747 (40.6%) 330 (20.0%) 294 (19.8%)
Current smoker 709 (20.6%) 329 (17.9%) 329 (19.9%) 366 (24.7%)
Family history 3
Yes 297 (8.62%) 304 (16.4%)
<0.001
144 (8.72%) 218 (14.7%)
<0.001No 2960 (85.9%) 1415 (76.4%) 1441 (87.2%) 1232 (82.9%)
Missing-Unknown 190 (5.5%) 133 (7.2%) 67 (4.1%) 36 (2.4%)
Use of NSAIDs/aspirin
Yes 1334 (38.7%) 604 (32.6%)
<0.001
- -
No 2000 (58.0%) 1184 (63.9%) - -
Missing 113 (3.3%) 64 (3.46%)
Hormone replacement
therapy use
Never - - 1469 (88.9%) 1347 (90.6%)
0.15Ever - - 126 (7.6%) 104 (7.0%)
Not Known (or not
remember) - - 57 (3.5%) 35 (2.4%)
Oral contraceptive use
No - - 839 (50.8%) 772 (52.0%)
0.52Yes - - 812 (49.2%) 712 (48.0%)
Age at menarche
<13 years old - - 667 (40.4%) 630 (42.4%)
<0.001≥13 years old - - 925 (56.0%) 837 (56.3%)
Not known - - 60 (3.6%) 19 (1.3%)
Number of children 1.9 (1.5) 1.7 (1.3) <0.001 2
Age at first pregnancy
Nulliparous - - 310 (18.8%) 317 (21.5%)
0.33
<20 years - - 58 (3.53%) 59 (4.0%)
20–24 years - - 407 (24.7%) 345 (23.4%)
25–29 years - - 537 (32.6%) 454 (30.8%)
>29 years - - 333 (20.2%) 301 (20.4%)
Menopausal status
Premenopausal - - 476 (28.8%) 532 (35.8%)
<0.001Postmenopausal - - 1175 (71.2%) 953 (64.2%)
BC, breast cancer; BMI, body mass index; CRC, colorectal cancer; E-DII; energy-adjusted dietary inflammatory
index; MCC, Multi-case-control Spain study; Non-enzymatic antioxidant capacity, NEAC; NSADs, nonsteroidal
anti-inflammatory drugs; TE, Trolox equivalents. 1 p-value obtained by Student t-test for continuous variables
normally distributed or chi-squared test for categorical variables unless otherwise indicated. 2 p-value obtained by
Wilcoxon rank-sum test for continuous variables non-normally distributed. 3 Only first relative degree colorectal
cancers or breast cancer.
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Table 2. Characteristics of participants in the control group (n = 3576) according to categories of
the energy-adjusted dietary inflammatory index (E-DII) score (based on the quartile distribution in
controls).
Variables Q1N = 894
Q2
N = 895
Q3
N = 892
Q4
N = 895 p-Value
1 n
Men (−5.11, −1.49) (−1.49, −0.167) (−0.167, 1.41) (1.41, 5.47)
Women (−5.64, −2.15) (−2.15, −1.01) (−1.01, 0.426) (0.426, 5.12)
mean(sd) / N(%) mean(sd) / N(%) mean(sd) / N(%) mean(sd) / N(%)
Age 65.3 (10.8) 64.5 (11.1) 63.0 (12.0) 58.6 (13.0) <0.001 2 3576
BMI (kg/m2) 26.9 (4.4) 26.7 (4.43) 26.4 (4.3) 26.4 (4.52) 0.05 3576
Energy intake (without
alcohol; kcal/day) 1627 (471) 1776 (495) 1841 (528) 1966 (581) <0.001 3576
Ethanol intake (g/day) 9.4 (12.8) 9.5 (13.3) 11.3 (16.6) 13.6 (19.3) <0.001 2 3576
Total dietary NEAC
(without coffee)
TEAC (µmol TE/day) 4.76 (1.95) 4.25 (1.74) 3.82 (1.68) 3.17 (1.53) <0.001 3450
Sex 1 3576
Men 455 (50.9%) 456 (50.9%) 455 (51.0%) 456 (50.9%)
Women 439 (49.1%) 439 (49.1%) 437 (49.0%) 439 (49.1%)
Education
<0.001
3576
Less than primary
school 171 (19.1%) 169 (18.9%) 147 (16.5%) 130 (14.5%)
Primary school 298 (33.3%) 299 (33.4%) 301 (33.7%) 245 (27.4%)
Secondary school 241 (27.0%) 233 (26.0%) 259 (29.0%) 316 (35.3%)
University 184 (20.6%) 194 (21.7%) 185 (20.7%) 204 (22.8%)
Tobacco smoking
<0.001
3562
Never smoker 445 (49.9%) 427 (48.0%) 389 (43.7%) 328 (36.8%)
Former smoker 316 (35.5%) 333 (37.5%) 312 (35.1%) 278 (31.2%)
Current smoker 130 (14.6%) 129 (14.5%) 189 (21.2%) 286 (32.1%)
Physical activity
<0.001
3540
Inactive 314 (35.4%) 303 (34.2%) 336 (38.1%) 405 (45.9%)
Moderately active 119 (13.4%) 137 (15.4%) 135 (15.3%) 139 (15.7%)
Active 107 (12.1%) 122 (13.8%) 102 (11.6%) 102 (11.6%)
Very active 347 (39.1%) 325 (36.6%) 310 (35.1%) 237 (26.8%)
Use of NSAIDs/aspirin
0.32
3576
Yes 346 (38.7%) 335 (37.4%) 353 (39.6%) 356 (39.8%)
No 515 (57.6%) 522 (58.3%) 512 (57.4%) 519 (58.0%)
Missing 33 (3.7%) 38 (4.3%) 27 (3.0%) 20 (2.2%)
Hormone replacement
therapy use
0.01
1754
Never 377 (85.9%) 383 (87.2%) 393 (89.9%) 407 (92.7%)
Ever 38 (8.7%) 40 (9.1%) 28 (6.4%) 26 (5.9%)
Not Known (or not
remember) 24 (5.5%) 16 (3.6%) 16 (3.7%) 6 (1.4%)
Oral contraceptive use
<0.001
1753
No 251 (57.2%) 247 (56.4%) 209 (47.8%) 196 (44.6%)
Yes 188 (42.8%) 191 (43.6%) 228 (52.2%) 243 (55.4%)
Age at menarche
0.30
1754
<13 172 (39.2%) 179 (40.8%) 166 (38.0%) 194 (44.2%)
≥13 247 (56.3%) 240 (54.7%) 259 (59.3%) 231 (52.6%)
Missing 20 (4.6%) 20 (4.6%) 12 (2.8%) 14 (3.2%)
Age at first pregnancy
0.30
1742
Nulliparous 73 (16.7%) 83 (19.1%) 76 (17.6%) 91 (20.8%)
<20 years 17 (3.9%) 11 (2.5%) 18 (4.2%) 15 (3.43%)
20–24 years 104 (23.8%) 122 (28.0%) 104 (24.0%) 103 (23.6%)
25–29 years 144 (33.0%) 142 (32.6%) 159 (36.7%) 133 (30.4%)
>29 years 99 (22.7%) 77 (17.7%) 76 (17.6%) 95 (21.7%)
Number of children 2.0 (1.5) 1.9 (1.4) 2.0 (1.5) 1.9 (1.4) 0.41 2 1750
Menopausal status
<0.001
1753
Premenopausal 81 (18.5%) 100 (22.8%) 128 (29.4%) 184 (41.9%)
Postmenopausal 358 (81.5%) 339 (77.2%) 308 (70.6%) 255 (58.1%)
E-DII; energy-adjusted dietary inflammatory index; BMI, body mass index; Non-enzymatic antioxidant capacity,
NEAC; NSADs, nonsteroidal anti-inflammatory drugs; TE, Trolox equivalents. 1 p-value obtained by Student t-test
for continuous variables normally distributed or chi-squared test for categorical variables unless otherwise indicated.
2 p-value obtained by Wilcoxon rank-sum test for continuous variables non-normally distributed.
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3.2. E-DII and Colorectal Cancer Risk
The OR and 95% CI for the association between E-DII and CRC risk, as well as according to the
location of the tumor and the stratified results, are presented in Table 3. A statistically significant
increased CRC risk was observed with increasing E-DII score per 1-point increment both in the
minimally (ORE-DII: 1.15, 95%CI: 1.11–1.19) and fully adjusted models (ORE-DII: 1.14, 95%CI: 1.10–1.18).
Participants classified at the fourth E-DII quartile were at higher risk of developing CRC (ORQ4vsQ1:
1.93, 95%CI: 1.60–2.32; p-value for trend: <0.001). This association was consistent when colon and rectal
CRC subtypes were evaluated using the continuous E-DII variable per 1-point increment (ORE-DII:
1.13, 95%CI: 1.08–1.17, and ORE-DII: 1.17, 95%CI: 1.11–1.22; respectively). Results remained unchanged
when we performed the three sensitivity analyses: (1) Excluding those participants who had more than
six months between the data of diagnosis and the interview (Table 3); (2) adjusting the final model by
energy intake from non-alcohol sources and alcohol consumption (data not shown); and (3) restricting
the analyses to non-drinkers (data not shown).
The E-DII score was statistically significant positively associated with CRC risk in both males
and females (p-value for trend: <0.001; LRT p-value: 0.04), but higher ORs were observed in men
(ORQ4vsQ1: 2.14, 95%CI: 1.68–2.73) than in women (ORQ4vsQ1: 1.57, 95%CI: 1.16–2.13) (Table 3).
Effect-measure modification by BMI, physical activity, NSAIDs/aspirin use, and tobacco smoking
was evaluated as these factors are related to inflammation and to CRC risk (Table 3). None of the LRT
p-values showed evidence for heterogeneity (all LRT p-values > 0.25).
3.3. E-DII and Breast Cancer Risk
Table 4 displays the crude and adjusted OR and 95% CI for the association between E-DII and
overall BC risk and BC subtypes, in addition to stratified analyses. A statistically significant increased
BC risk was observed in the minimally adjusted model (ORE-DII: 1.05, 95%CI: 1.01–1.09; ORQ4vsQ1:
1.25, 95%CI: 1.02–1.55; p-value for trend: 0.06) but not in the fully adjusted model, where confidence
limits overlapped unity (ORE-DII: 1.04, 95%CI: 1.00–1.08; ORQ4vsQ1: 1.22, 95%CI: 0.99–1.52; p-value for
trend: 0.10). Sensitivity analyses did not alter the final model results and even when we excluded
those BC cases that had more than six months between the data of diagnosis and the interview, results
were not statistically significant (Table 4).
BC subtypes (HR+, HER2+, TN) also were investigated. No associations were found between
E-DII (measured both as a continuous and categorical) and HR+ and TN subtypes. A statistically
significant increased HER2+ risk was observed when E-DII was evaluated as a categorical variable
(ORQ4vsQ1: 1.56, 95%CI: 1.01–2.04); however, there was no evidence of a linear dose response trend
(p-value: 0.24) (Table 4).
Despite observing some individual statistically significant ORs among inactive (ORQ4vsQ1: 1.48,
95%CI: 1.04–2.10, p-value for trend: >0.13) and postmenopausal women (ORE-DII: 1.06, 95%CI:
1.01–1.12), no consistent evidence for effect-measure modification was observed by menopausal status,
HRT and OC use, BMI, physical activity, and tobacco smoking (all LRT p-values > 0.15) (Table 4).
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Table 3. Association between E-DII score and colorectal cancer in the MCC-Spain Study (n = 5299).
Control/Cases Models
E-DII Score Categories
p for Trend p for InteractionPer 1-Point
Increment in the
E-DII Score
Q1 Q2 Q3 Q4
M ≤−1.49 (−1.49, −0.167) (−0.167, 1.41) >1.41
W ≤−2.15 (−2.15, −1.01) (−1.01, 0.426) >0.426
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
All 3447/1852 Simple 1.15 (1.11–1.19) 1.00 (ref) 1.59 (1.33–1.89) 1.99 (1.67–2.37) 2.03 (1.70–2.44) <0.001
3399/1842 Final 1.14 (1.10–1.18) 1.00 (ref) 1.57 (1.31–1.89) 1.97 (1.64–2.35) 1.93 (1.60–2.32) <0.001
3399/1596 Sensitivity 1.15 (1.11–1.19) 1.00 (ref) 1.66 (1.37–2.01) 2.06 (1.70–2.49) 2.02 (1.66–2.47) <0.001
CRC Subtype 1
Colon cancer 3399/1122
Final
1.13 (1.08–1.17) 1.00 (ref) 1.53 (1.24–1.89) 1.86 (1.51–2.30) 1.81 (1.45–2.26) <0.001
Rectal cancer 3399/700 1.17 (1.11–1.22) 1.00 (ref) 1.69 (1.29–2.22) 2.23 (1.71–2.90) 2.27 (1.73–2.98) <0.001
Sex
Men 1748/1174
Stratified 1
1.14 (1.09–1.19) 1.00 (ref) 1.72 (1.36–2.18) 2.02 (1.60–2.57) 2.14 (1.68–2.73) <0.001
0.04Women 1651/668 1.12 (1.05–1.18) 1.00 (ref) 1.39 (1.05–1.86) 1.95 (1.47–2.59) 1.57 (1.16–2.13) <0.001
BMI (kg/m2)
Normal weight 1308/544
Stratified 2
1.12 (1.06–1.19) 1.00 (ref) 1.52 (1.09–2.12) 1.75 (1.26–2.44) 1.95 (1.39–2.73) <0.001
0.87Overweight and Obese 2091/1298 1.14 (1.10–1.19) 1.00 (ref) 1.58 (1.27–1.97) 2.06 (1.66–2.55) 1.90 (1.51–2.37) <0.001
Physical activity 2
Inactive 1310/945
Stratified 3
1.17 (1.08–1.20) 1.00 (ref) 1.69 (1.28–2.24) 2.31 (1.76–3.03) 2.05 (1.55–2.70) <0.001
0.52Active 2089/897 1.15 (1.09–1.20) 1.00 (ref) 1.50 (1.18–1.91) 1.78 (1.39–2.26) 1.92 (1.49–2.47) <0.001
Use of NSAIDs/aspirin
Yes 1298/601
Stratified 4
1.14 (1.07–1.20) 1.00 (ref) 1.73 (1.26–2.37) 1.94 (1.42–2.65) 1.97 (1.43–2.72) <0.001
0.25No 1990/1178 1.13 (1.08–1.18) 1.00 (ref) 1.49 (1.18–1.88) 1.97 (1.57–2.47) 1.83 (1.44–2.32) <0.001
Tobacco smoking
Current/Former smokers 1893/1076
Stratified 5
1.09 (1.05–1.14) 1.00 (ref) 1.61 (1.26–2.07) 1.87 (1.47–2.39) 1.72 (1.34–2.20) <0.001
0.58Never smokers 1506/766 1.18 (1.12–1.25) 1.00 (ref) 1.53 (1.17–2.00) 2.05 (1.57–2.68) 2.11 (1.58–2.82) <0.001
BMI, body mass index; CRC, colorectal cancer; E-DII; energy-adjusted dietary inflammatory index; M, men; MCC, Multi-case-control Spain study; NEAC, dietary non-enzymatic total
antioxidant capacity; NSADs, nonsteroidal anti-inflammatory drugs; W, women. Simple model: Logistic regression analyses adjusted for sex (except in models stratified by gender), age,
educational level, and study area. Final model: Logistic regression analyses adjusted for sex, age, educational level, study area, family history of colorectal cancer, tobacco smoking,
physical activity, BMI, and NSAIDs/aspirin use. Sensitivity analysis excluding cases that had more than 6 months between the data of diagnosis and the interview: Logistic regression
analyses adjusted for the same variables as Final model. Stratified 1: Logistic regression analyses adjusted, age, educational level, study area, family history of colorectal cancer, tobacco
smoking, physical activity, BMI, and NSAIDs/aspirin use. Stratified 2: Logistic regression analyses adjusted for sex, age, educational level, study area, family history of colorectal cancer,
tobacco smoking, physical activity, and NSAIDs/aspirin use. Stratified 3: Logistic regression analyses adjusted for sex, age, educational level, study area, family history of colorectal cancer,
tobacco smoking, BMI, and NSAIDs/aspirin use. Stratified 4: Logistic regression analyses adjusted for sex, age, educational level, study area, family history of colorectal cancer, tobacco
smoking, physical activity, and BMI. Stratified 5: Logistic regression analyses adjusted for sex, age, educational level, study area, family history of colorectal cancer, physical activity, BMI,
and NSAIDs/aspirin use. 1 In 20 colorectal cancer cases, tumor subtype was not available, hence were excluded. 2 Categorized as inactive and active (including "moderately active",
"active”, and "very active").
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Table 4. Association between E-DII score and breast cancer in the MCC-Spain Study (n = 3138) .
Control/Case Models
E-DII Score Categories
p for Trend p for InteractionPer 1-Point Increment
in the E-DII Score
Q1 Q2 Q3 Q4
≤−2.15 (−2.15, −1.01) (−1.01, 0.426) >0.426
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
All women 1652/1486 Simple 1.05 (1.01–1.09) 1.00 (ref) 1.17 (0.95–1.45) 1.13 (0.92–1.39) 1.25 (1.02–1.55) 0.06
1628/1471 Final 1.04 (1.00–1.08) 1.00 (ref) 1.16 (0.94–1.43) 1.13 (0.91–1.39) 1.22 (0.99–1.52) 0.10
1628/1140 Sensitivity 1.03 (0.99–1.08) 1.00 (ref) 1.17 (0.93–1.47) 1.09 (0.87–1.37) 1.19 (0.94–1.50) 0.24
BC subtypes
HR+ 1 1628/986 Final 1.04 (0.99–1.09) 1.00 (ref) 1.17 (0.92–1.49) 1.17 (0.93–1.49) 1.22 (0.95–1.55) 0.14
HER2+ 1 1628/251 Final 1.04 (0.96–1.13) 1.00 (ref) 1.85 (1.21–2.83) 1.27 (0.81–1.98) 1.56 (1.01–2.04) 0.24
TN1 1628/105 Final 1.02 (0.91–1.14) 1.00 (ref) 0.67 (0.37–1.23) 0.78 (0.44–1.39) 0.99 (0.56–1.75) 0.97
Menopausal status
Premenopausal 469/526
Stratified 1
1.01 (0.94–1.08) 1.00 (ref) 0.94 (0.60–1.47) 0.97 (0.64–1.48) 1.05 (0.70–1.57) 0.71
0.33Postmenopausal 1159/945 1.06 (1.01–1.12) 1.00 (ref) 1.23 (0.97–1.58) 1.19 (0.93–1.54) 1.30 (0.99–1.69) 0.08
HRT use
Never 1448/1335
Stratified 2
1.04 (1.00–1.08) 1.00 (ref) 1.16 (0.93–1.46) 1.16 (0.92–1.45) 1.22 (0.97–1.53) 0.11
0.54Ever 125/103 1.12 (0.93–1.34) 1.00 (ref) 0.88 (0.38–2.05) 1.12 (0.47–2.64) 1.47 (0.62–3.49) 0.35
OC use
No 828/764
Stratified 3
1.05 (0.99–1.11) 1.00 (ref) 1.25 (0.94–1.66) 1.35 (1.01–1.81) 1.20 (0.88–1.63) 0.18
0.87Yes 800/707 1.04 (0.98–1.10) 1.00 (ref) 1.10 (0.79–1.52) 0.97 (0.71–1.33) 1.25 (0.91–1.71) 0.25
BMI (kg/m2)
Normal weight 843/718
Stratified 4
1.04 (0.98–1.10) 1.00 (ref) 0.88 (0.64–1.21) 1.01 (0.74–1.38) 1.20 (0.88–1.63) 0.15
0.99Overweight and Obese 785/753 1.05 (0.99–1.12) 1.00 (ref) 1.49 (1.11–2.01) 1.25 (0.93–1.68) 1.29 (0.95–1.76) 0.23
Physical activity 2
Inactive 625/608
Stratified 5
1.06 (0.99–1.12) 1.00 (ref) 1.92 (1.33–2.78) 1.63 (1.14–2.34) 1.48 (1.04–2.10) 0.13
0.92Active 1003/863 1.03 (0.97–1.09) 1.00 (ref) 0.93 (0.71–1.21) 0.90 (0.69–1.18) 1.14 (0.86–1.51) 0.45
Tobacco smoking
Current/Former smokers 647/656
Stratified 6
1.05 (0.98–1.11) 1.00 (ref) 0.85 (0.59–1.22) 1.01 (0.71–1.44) 1.15 (0.81–1.61) 0.21
0.15Never smokers 981/815 1.03 (0.97–1.09) 1.00 (ref) 1.40 (1.07–1.82) 1.19 (0.91–1.57) 1.19 (0.89–1.59) 0.39
BMI, body mass index; CRC, colorectal cancer; E-DII; energy-adjusted dietary inflammatory index; HRT, hormone replacement therapy; MCC, Multi-case-control Spain study; NSADs,
nonsteroidal anti-inflammatory drugs; OC, oral contraceptive. Simple model: Logistic regression analyses adjusted for age, study area, and educational level. Final model: Logistic
regression analyses adjusted for age, study area, educational level, family history of breast cancer, tobacco smoking, HRT use, OC use, age at menarche, age at first pregnancy, number of
children, menopausal status, physical activity, and BMI. Sensitivity analysis excluding cases that had more than six months between the data of diagnosis and the interview: Logistic
regression analyses adjusted for the same variables as Final model. Stratified 1: Logistic regression analyses adjusted for age, study area, educational level, family history of breast cancer,
tobacco smoking, HRT use, OC use, age at menarche, age at first pregnancy, number of children, physical activity, and BMI. Stratified 2: Logistic regression analyses adjusted for age, study
area, educational level, family history of breast cancer, tobacco smoking, OC use, age at menarche, age at first pregnancy, number of children, menopausal status, physical activity, and BMI.
Stratified 3: Logistic regression analyses adjusted for age, study area, educational level, family history of breast cancer, tobacco smoking, HRT use, age at menarche, age at first pregnancy,
number of children, menopausal status, physical activity, and BMI. Stratified 4: Logistic regression analyses adjusted for age, study area, educational level, family history of breast cancer,
tobacco smoking, HRT use, OC use, age at menarche, age at first pregnancy, number of children, menopausal status, and physical activity. Stratified 5: Logistic regression analyses
adjusted for age, study area, educational level, family history of breast cancer, tobacco smoking, HRT use, OC use, age at menarche, age at first pregnancy, number of children, menopausal
status, and BMI. Stratified 6: Logistic regression analyses adjusted for age, study area, educational level, family history of breast cancer, HRT use, OC use, age at menarche, age at first
pregnancy, number of children, menopausal status, physical activity, and BMI. 1 HR+: hormone receptor positive tumors (ER+ or PR+ with HER2-); HER2+: human epidermal growth
factor receptor positive tumors, independent of ER or PR; TN: triple negative tumors (ER-, PR-, and HER2-). In 131 breast cancer cases, tumor subtype was not available, hence were
excluded. 2 Categorized as inactive and active (including "moderately active", "active”, and "very active")
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3.4. E-DII, NEAC, and Colorectal and Breast Cancer Risk
The correlation coefficient between E-DII and NEAC in the MCC-Spain study was −0.32
(p-value < 0.001). The ORs and 95% CI for the association between the inflammatory and antioxidant
profile (combining information on E-DII and dietary NEAC) and CRC and BC risk are presented in
Table 5. The inflammatory and antioxidant profile ranged from 0 (less inflammatory, high antioxidant)
to 6 (high inflammatory and less antioxidant). The continuous variable (1-point increment in the
E-DII+NEAC profile) included 1798 CRC cases and 3312 controls and showed a statistically significant
10% increasing risk. Participants classified at the highest category of the score (including 499 cases and
790 controls) compared to the first category (including 642 cases and 1404 controls) had higher risk of
developing CRC (ORQ4vsQ1: 1.48, 95%CI: 1.26–1.74; p-value for trend: <0.001).
Results regarding BC risk showed a non-statistically significant increased risk when the profile was
evaluated continuously (OR: 1.02, 95%CI: 0.98–1.07), as well as for participants classified at the fourth
quartile (399 cases and 388 controls) compared to the first quartile (563 cases and 673 controls) (ORQ4vsQ1:
1.09, 95%CI: 0.90–1.32, p-value for trend: 0.39). Similar results for both outcomes were obtained when
the combined categorical variable was used as the main exposure variable (Supplemental Table S1).
No evidence for effect-measure modification was observed in CRC models by low vs. high fiber,
vegetables, and meat consumers (all LRT p-values > 0.05; Supplemental Table S2). Likewise, in BC
models, none of the LRT p-values showed evidence for heterogeneity when low vs. high fiber and
vegetables consumers were evaluated (LRT p-values > 0.28; Supplemental Table S2). However, there
was statistically significant heterogeneity by meat intake (LRT p-value: 0.004). Those women who
had higher values of meat consumption (above the median: ≥67 grams/day), had a 9% increased
BC risk for each increment in the E-DII+NEAC score profile. High meat consumers classified at the
highest category of the score (including 270 cases and 207 controls) had higher risk of developing BC
(ORQ4vsQ1: 1.43, 95%CI: 1.10–1.85; p-value for trend: <0.001).
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Table 5. Association between E-DII score and dietary non-enzymatic antioxidant capacity (NEAC) and colorectal and breast cancer in the MCC-Spain Study.
Control/Case Models
E-DII+NEAC Score Categories
p for Trend
≤2 3 4 ≥5
Per 1-Point Increment
in the E-DII+NEAC
Score
M: mean E-DII −1.49 −0.12 0.80 2.15
W: mean E-DII −2.12 −0.89 −0.16 1.28
M: mean TEAC 5.68 4.11 3.45 2.39
W: mean TEAC 4.93 3.68 3.02 2.19
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
CRC 3312/1798 Final-CRC 1.10 (1.06–1.14) 1.00 (ref) 1.31 (1.10–1.55) 1.32 (1.10–1.58) 1.48 (1.26–1.74) <0.001
CRC Subtype 1
Colon cancer 3312/1100 Final-CRC 1.09 (1.05–1.14)1. 1.00 (ref) 1.31 (1.07–1.60) 1.29 (1.04–1.60) 1.46 (1.21–1.76) <0.001
Rectal cancer 3312/678 Final-CRC 1.11 (1.06–1.17) 1.00 (ref) 1.29 (1.01–1.65) 1.34 (1.04–1.73) 1.49 (1.19–1.87) <0.001
BC 1585/1418 Final-BC 1.02 (0.98–1.07) 1.00 (ref) 0.98 (0.80–1.22) 1.03 (0.82–1.28) 1.09 (0.90–1.32) 0.39
Menopausal status
Premenopausal 464/506 Stratified 1 0.98 (0.91–1.06) 1.00 (ref) 1.04 (0.68–1.57) 0.88 (0.58–1.33) 0.91 (0.66–1.27) 0.50
Postmenopausal 1121/912 Stratified 1 1.05 (0.99–1.11) 1.00 (ref) 0.95 (0.74–1.22) 1.12 (0.85–1.48) 1.22 (0.95–1.56) 0.10
BC, breast cancer; CRC, colorectal cancer; E-DII; energy-adjusted dietary inflammatory index; M, men; MCC, Multi-case-control Spain study; NEAC, dietary non-enzymatic total
antioxidant capacity; TE, Trolox equivalents; W, women, Final model (CRC): Logistic regression analyses adjusted for sex, age, educational level, study area, family history of colorectal
cancer, tobacco smoking, physical activity, BMI, and NSAIDs/aspirin use. Final model (BC): Logistic regression analyses adjusted for age, study area, educational level, family history
of breast cancer, tobacco smoking, HRT use, OC use, age at menarche, age at first pregnancy, number of children, menopausal status, physical activity, and BMI. Stratified 1: Logistic
regression analyses adjusted for age, study area, educational level, family history of breast cancer, tobacco smoking, HRT use, OC use, age at menarche, age at first pregnancy, number of
children, physical activity, and BMI. 1 In 20 colorectal cancer cases, tumor subtype was not available, hence were excluded.
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4. Discussion
This large case-control study in Spain provided further evidence that a pro-inflammatory diet
(measured by the widely used E-DII) was clearly associated with increased CRC risk, and this risk was
persistently shared across different tumor locations and all subgroups that were evaluated. Results
regarding risk of BC do not support the hypothesis of an association; although non-statistically
significant increased risks were observed when E-DII was analyzed both as a continuous variable and
by quartiles. This study, including both outcomes, observed no changes when sensitivity analyses
were carried out and did not observe evidence for effect-measure modification when subgroups
were analyzed.
The epidemiologic evidence on the association between DII and CRC risk has been reported in 4
prospective [42–45], 5 case-controls studies [46–50], and several meta-analyses [29,30,51,52]. Despite
the type of study design (case-control or prospective cohorts), the differences in the total number of
food/nutrients items included in the previously reported DII scores, and the different DII-approaches
used as the main exposure variable (with and without energy-adjustment), results reflect that a greater
dietary inflammatory potential is related to CRC risk, and this effect tends to be more pronounced in
men than in women. The present study is the first epidemiologic study that replicates these results
using the E-DII score in Spanish populations.
Several dietary components and dietary patterns have been associated with CRC risk [5]. A total
of 9 of the 45 possible items that comprise the DII score are pro-inflammatory: energy, carbohydrates,
protein, total fat, saturated fat, trans fat, cholesterol, vitamin B12, and iron [19]. Most of these items
are related to Western-style diets, which have been associated with inflammation [53]. In agreement
with our results, a recent paper from our colleagues, Castelló, et al showed that a high adherence
to the Western dietary pattern was statistically significant positive associated with overall CRC risk
(ORQ4vsQ1: 1.50, 95%CI: 1.20–1.87), whereas a high adherence to the Mediterranean diet was inversely
associated (ORQ4vsQ1: 0.65, 95%CI: 0.53–0.80). Likewise, similar relative risks were observed for both
patterns among males and females [54].
The development and progression of BC has been linked, among other parameters, to inflammation [55].
The evidence regarding the association between DII and overall BC risk is still inconclusive despite being
evaluated in several prospective cohorts [31,32,56–58], case-control studies [59–63], and cancer-specific
and general meta-analyses [30,64–66]. Although our estimates suggested increased relative risks for the
association between E-DII and overall BC, the 95% CIs included the null value. Our highest quartile of E-DII
did not include very high E-DII values, and this may have limited our capability to observe statistically
significant associations. Moreover, two recent reviews and meta-analysis have observed significant
associations between high vs. low inflammatory diet in postmenopausal women but no for premenopausal
women [65,66]. The present study also observed a significant association among postmenopausal women
when E-DII was evaluated continuously, but no effect-measure modification was observed by menopausal
status. Likewise, the observed results may have been influenced by alcohol consumption. During the
calculation of the DII and E-DII score, alcohol is negatively weighted (meaning low inflammation), and
alcohol consumption is considered an important risk factor for BC [67]. We performed a sensitivity analysis
further adjusting for alcohol intake and total energy (without alcohol), and we restricted the analysis to
non-drinkers; however, results were not altered. Further studies evaluating BC risk or survival should
consider calculating the DII or the E-DII without accounting for alcohol intake.
Our study adds value to the scientific evidence because, up to now, none of the epidemiological
studies cited above have evaluated the association between E-DII and cancer risk taking into account
the total anti-oxidant dietary content. Dietary NEAC intake has been associated with a decreased
risk of CRC in two large case-control studies, including the MCC-study [28,35]; whereas inconclusive
results were observed in two prospective cohorts [33,34]. The association between dietary NEAC and
BC is also doubtful. To our knowledge, only two studies have reported results: A prospective study
showing a significant decreased risk [37] and a case-control study, which observed null associations [36].
Inflammation and oxidative stress are two mechanisms that have been independently related to cancer
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risk [68,69]; however, they are closely tied [14,70]. The profile score, including information on E-DII
and dietary NEAC, showed consistent and significant increased effect estimates of CRC in all categories,
as well as per 1-point increment in the score, suggesting that both E-DII and NEAC are linked to CRC
risk. However, relative risks were slightly attenuated compared to those obtained when E-DII was used
as the main exposure variable. Results for BC risk remained elevated, but not statistically significant.
Likewise, a similar pattern was observed; i.e., relative risks were somewhat lower. Similar relative
risks were observed when a combined variable (low E-DII and high TEAC vs high E-DII and low
TEAC) was used instead of the profile score. This may indicate that E-DII plays a stronger effect on
CRC and BC risk than NEAC, or that the E-DII and NEAC profile needs to be assessed in other ways.
When the analyses were restricted to high/low consumers of vegetables, fiber, and meat, no evidence
for heterogeneity was observed for CRC risk. Similar results were observed for BC risk; however,
we found a statistically significant interaction between E-DII+NEAC score and meat intake. Women in
the highest quartile of the score and were higher meat consumers were at higher BC risk . Although
meat intake per se is not taken into account in the construction of the DII, meat-derived macronutrients
and micronutrients are included as pro-inflammatory factors. Thus, higher consumption of meat
results in higher E-DII values (and consequently higher E-DII+NEAC values). In addition, this category
included more BC cases than controls (270 vs. 207). Meat intake has also been associated with increased
BC risk in the MCC-Spain study, especially among postmenopausal women [71]. These findings could
indicate a synergistic effect of meat consumption and having a pro-inflammatory and pro-oxidant diet
on BC risk. Nonetheless, further research is warranted in this field to confirm these findings.
This study is based on a relatively large sample size that enabled us to investigate specific colorectal
and breast tumor subtypes, as well as different subgroups (i.e., menopausal status, physical activity,
NSAIDs/aspirin use). Additionally, we have used a valid tool to assess the inflammatory potential of
the diet, which has been investigated in many different studies, regions and different outcomes [72].
Notwithstanding its strengths, there are some weaknesses in our study that should be mentioned.
Case-control designs are prone to selection and recall biases. The MCC-study was designed with the
goal of minimizing selection biases by recruiting population-based controls and cases [38]. Regarding
recall bias, the dietary information collected at recruitment referred to the preceding year, and sensitivity
analysis were carried out excluding CRC and BC cases diagnosed within less than six months between
the date of diagnosis. When we did this, results did not differ substantially. Measurement error also
may be present in our dietary data; nonetheless, the MCC-study assessed the dietary information by
using a self-reported FFQ validated for Spanish population. As in that work, the DII derived from
the MCC-Study was energy-adjusted and included only 30 of the 45 food/nutrient parameters, and
we expressed the E-DII as quartiles based on the sex-specific distribution within the control group.
Thus, direct comparison to other E-DII/DII quantile categorizations is challenging: Most of the studies
assessed the inflammatory potential of the diet using the DII (energy was included in the score or
as a covariate in final models); depending on the study, the E-DII/DII score was estimated including
different number of food/nutrient parameters; other approaches have been used to estimate E-DII
besides the one published by Shivappa et al. [44]; and only a few studies presented sex-specific E-DII/DII
values. Despite these limitations, our E-DII range values in men are wider than the ones reported by the
case-control study in Iran [73]. In women, our E-DII values are slightly lower than the ones reported
by the case-control study in Germany; however, that study only included postmenopausal women [32].
No data on inflammatory biomarkers are available in the MCC-study; therefore, we could not conduct
a validation analysis within our study. Finally, it should be acknowledged that several subgroups have
been studied (i.e., E-DII and NEAC profile), and thus, some results might be due to chance.
5. Conclusions
In conclusion, the present study adds further evidence on the association between CRC risk and
the inflammatory potential of the diet, as well as the combined effect of the inflammatory potential of
the diet and its total dietary antioxidant capacity. The increased risk between these dietary scores and
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BC were not statistically significant. Additional studies with larger sample size should be performed
to elucidate any possible association.
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